domingo, 11 de outubro de 2026
PesquisarExplore
pt.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· July 29, 2026

RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET

View original at globenewswire.com
“a record $563,000 of sales in the first quarter of 2026”
Verbatim excerpt from the source · GlobeNewswire · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • RenovoRx anticipates full enrollment in the TIGeR-PaC trial in the very near term and final data readout in mid-to-late 2027.

    60% confidence

  • RenovoRx management will discuss the Company's growing revenues from commercial sales of RenovoCath as a standalone drug-delivery device, as well as increased RenovoCath adoption at high-volume U.S. cancer centers and a broader base of repeat orders from existing customers.

    60% confidence

Citado nestas reportagens da Via News

O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Agentic AI Rewires Enterprise Software: Platform Incumbents, Governance, and a Funded Startup Wave
Enterprise software is being rebuilt around autonomous AI agents. Incumbents and large platforms (SAP with its Autonomous Suite and Joule, Zeta with AthenaOS/AIM/Athena MCP, Meta with its new Enterprise Platform) are racing to own the agent layer. Meanwhile, seed and Series A money flows to finance-office and vertical startups (Dextr, Latitude, Dentira, Light), and consolidation continues through acquisitions (Tiny–Oso Cloud, Harvey–Guardrails AI). Investor commentary stresses that AI is better at disrupting around the edges of systems of record than at replacing them, that it should not be trusted with finance calculations, and that governance must be enforced by the system rather than left to agents.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,369 documentos-fonte arquivados
Consulte estes dados → isubstrate.com